Newly-released Gastro-retentive Drug Delivery Systems industry analysis report by Future Market Insights reveals that global sales of Gastro-retentive Drug Delivery Systems in 2022 were held at USD 13.3 Billion. With a CAGR of 10.1% from 2023 to 2033, the market is expected to reach USD 24.8 Billion by 2033. Floating Drug Delivery System is expected to be the highest revenue generating type, with a CAGR of 5% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Gastro-retentive Drug Delivery Systems Market (2023) | USD 14 Billion |
| Global Gastro-retentive Drug Delivery Systems Market (2033) | USD 24.8 Billion |
| Global Gastro-retentive Drug Delivery Systems Market CAGR (2023 to 2033) | 10.1% |
| USA Gastro-retentive Drug Delivery Systems Market CAGR (2023 to 2033) | 6% |
| Key Companies Profiled | F. Hoffmann La Roche; Glaxo Smith Kline; Lupin; Pfizer; Sun Pharma; Ranbaxy; Depomed; Galanix; Pharmacia |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Gastro-retentive Drug Delivery Systems industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, market value of the Gastro-retentive Drug Delivery Systems industry increased at a CAGR of around 8.6%, wherein, countries such as the USA, China, Japan, United kingdom and South Korea held a significant share in the global market.
Rising disease burden throughout the world and the proven efficacy of GRDDS in addressing several gastric-related disorders such as gastric ulcers, and peptic ulcers, are some of the key reasons driving the market growth. Owing to this, the gastro-retentive Drug Delivery Systems market is projected to grow at a CAGR of 10.1% over the coming 10 years.
Manufacturing systems, formulation approaches, storage systems, and technologies involved in transporting a drug to its gastrointestinal target site make gastro-retentive drug delivery global sales. Medical professionals are making use of the principles of production, rental property, locality of prescription, metabolism, and toxicity to boost the safety and potency of a drug delivery system. By making use of a gastro-retentive delivery system, illnesses can be prevented and treated using nutrients.
Large drug firms' investments to enhance gastro-retentive drug-delivery systems, along with the reduction in required doses due to enhanced bioavailability and an increase in the requirements for medications, have helped accelerate the market growth.
The well-established efficacy of gastro-retentive drug delivery systems in treating a variety of stomach disorders such as peptic ulcer and gastric ulcer, as well as a growth in the incidence of H. Pylori infection, which can cause gastritis and gastric cancer, impart a significant impact on the market.
Gastro-retentive drug distribution technology has proven to be a useful way of regulating the administration of a wide range of medicinal substances while enhancing bioavailability. Advancements in controlled oral medication administration systems have been made in recent years because of technological advancements that overcome physical roadblocks such as unpredictable stomach emptying periods and short gastric residency times. By extending their dwell time in the upper GI tract, once-GRDDS can enhance oral bioavailability and therapeutic excellence.
Technological advancements for rate-controlled oral medication delivery systems are now overcoming physiological issues such as unexpected stomach emptying intervals and short gastric residency times. To address these issues, the gastro-retentive drug delivery system is designed for a longer stomach retention duration, which increases patient preference by extending the time available for medicine absorption.
Principal Consultant
North America is expected to account for significant revenue in gastro-retentive drug delivery systems market, with a market projection of USD 10 Billion. Regional expansion is expected to be facilitated by the introduction of improved gastro-retentive medication delivery technology and the implementation of novel treatment techniques in healthcare.
GRDDS are projected to be in high demand as the prevalence of gastrointestinal disorders grows in the United States and Canada, as they lengthen medication retention time in the stomach. Demand for these devices in the region is projected to be driven by the presence of a large patient pool. Rising research and development spending in emerging markets is expected to drive regional market expansion.
Gastro-retentive Drug Delivery Systems Market in the US is expected to grow at a CAGR of 6% during the forecast period. The high prevalence of gastric cancer in the United States, as well as increasing research and development investment have contributed to the large market in the country.
The market in the United kingdom is expected to reach a valuation of USD 1 Billion by 2033. Growing with a CAGR of 6.1% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around USD 400 Million.
In Japan, the market is expected to grow at a CAGR of 7.2% from 2023 to 2033, reaching around USD 1 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of USD 500 Million during the forecast period.
The market in South Korea is expected to reach a valuation of around USD 700 Million by 2033, growing at a CAGR of 7.3% from 2023 to 2033. The market in the country is expected to witness an absolute dollar opportunity of around USD 400 Million.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Floating Drug Delivery systems are expected to account for significant market revenue and are expected to grow at a CAGR of 5% during the forecast period. Using floating medication delivery devices is one of the most important ways for improving stomach retention and drug bioavailability. Due to this, the system has a lower bulk density than gastric fluids, it may stay buoyant in the stomach for extended periods of time without interfering with the process of gastric emptying.
This mechanism gradually and at a predetermined rate delivers the drug. When medicine is administered, the stomach's residual system is emptied. This improves segmental development by lengthening stomach retention and better control over changes in plasma medicine concentration.
Manufacturers will benefit from proprietary benefits such as industry research financing and product development agreements, which will help them contribute to the development of effective cancer diagnosis technologies. Obtaining patents and government clearances for new technology will also continue to be a key growth strategy.
The key players in the market include Ranbaxy, F. Hoffmann La Roche, Pharmacia, GlaxoSmithKline, Lupin, Pfizer, Depomed, Galanix, Sun Pharma, and Alcon, Inc.
Few of the recent developments of key Gastro-retentive Drug Delivery Systems providers are as follows:
Similarly, recent developments related to companies offering Gastro-retentive Drug Delivery Systems have been tracked by the team at Future Market Insights, which are available in the full report.
The market is expected to attain a value of USD 14 billion in 2023.
Large drug firms' investments and technological advancements are driving the market growth.
North America is expected to offer significant opportunity for gastro-retentive drug delivery systems.
Floating drug delivery systems are highly preferred in the market.
The South Korea market is expected to expand at a CAGR of 7.3%.
1. Executive Summary
2. Market Overview
3. Market Background
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. High Density System
5.2. Expandable Drug Delivery System
5.3. Bioadhesive Drug Delivery System
5.4. Floating Drug Delivery System
5.5. Other Types
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form
6.1. Tablets
6.2. Liquid
6.3. Microspheres
6.4. Capsule
6.5. Other Dosage Forms
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Online Pharmacies
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. North America
8.2. Latin America
8.3. Europe
8.4. Asia Pacific
8.5. Middle East and Africa
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14. Key Countries Market Analysis
15. Market Structure Analysis
16. Competition Analysis
16.1. F. Hoffmann La Roche
16.2. Ranbaxy
16.3. GlaxoSmithKline
16.4. Pharmacia
16.5. Depomed
16.6. Alcon, Inc.
16.7. Lupin
16.8. Galanix
16.9. Sun Pharma
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Gastro-retentive Drug Delivery Systems Market
